scholarly journals Establishment of prognostic nomograms based on skeletal muscle index and serum biomarker in breast cancer patients receiving radiotherapy

2020 ◽  
Vol 10 (2) ◽  
Author(s):  
Xin Hua ◽  
Xin Huang ◽  
Zhang‐Zan Huang ◽  
Chen‐Ge Song ◽  
Jia‐Peng Deng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Skeletal Muscle ◽  
Cancer Patients ◽  
Serum Biomarker ◽  
Breast Cancer Patients ◽  
Skeletal Muscle Index

scholarly journals Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1806
Author(s):  
Byung Min Lee ◽  
Yeona Cho ◽  
Jun Won Kim ◽  
Sung Gwe Ahn ◽  
Jee Hung Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Skeletal Muscle ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Skeletal Muscle Index ◽  
Skeletal Muscle Loss ◽  
The Impact ◽  
Response To Neoadjuvant Chemotherapy

There are no means to predict patient response to neoadjuvant chemotherapy (NAC); the impact of skeletal muscle loss on the response to NAC remains undefined. We investigated the association between response to chemotherapy and skeletal muscle loss in breast cancer patients. Patients diagnosed with invasive breast cancer who were treated with NAC, surgery, and radiotherapy were analyzed. We quantified skeletal muscle loss using pre-NAC and post-NAC computed tomography scans. The response to treatment was determined using the Response Evaluation Criteria in Solid Tumors. We included 246 patients in this study (median follow-up, 28.85 months). The median age was 48 years old (interquartile range 42–54) and 115 patients were less than 48 years old (46.7%). Patients showing a complete or partial response were categorized into the responder group (208 patients); the rest were categorized into the non-responder group (38 patients). The skeletal muscle mass cut-off value was determined using a receiver operating characteristic curve; it showed areas under the curve of 0.732 and 0.885 for the pre-NAC and post-NAC skeletal muscle index (p < 0.001 for both), respectively. Skeletal muscle loss and cancer stage were significantly associated with poor response to NAC in locally advanced breast cancer patients. Accurately measuring muscle loss to guide treatment and delaying muscle loss through various interventions would help enhance the response to NAC and improve clinical outcomes.

Skeletal muscle loss and prognosis of breast cancer patients

2017 ◽  
Vol 25 (7) ◽  
pp. 2221-2227 ◽  
Author(s):  
Yoshiko Kubo ◽  
Tateaki Naito ◽  
Keita Mori ◽  
Gakuji Osawa ◽  
Etsuko Aruga
Keyword(s):  
Breast Cancer ◽  
Skeletal Muscle ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Skeletal Muscle Loss

scholarly journals N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.

2021 ◽  
Author(s):  
Lucy K Shewell ◽  
Christopher J. Day ◽  
Jamie R Kutasovic ◽  
Jodie L Abrahams ◽  
Jing Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Specific Binding ◽  
High Sensitivity ◽  
Disease Recurrence ◽  
Serum Biomarker ◽  
Breast Cancer Patients ◽  
Sialic Acid Binding

N-glycolylneuraminic acid (Neu5Gc) is an aberrant glycosylation that has been proposed as a cancer biomarker. Using a Neu5Gc-specific lectin called SubB2M in a Surface Plasmon Resonance (SPR)-based assay, we previously reported elevated Neu5Gc biomarkers in serum from ovarian cancer patients. Here we report an optimized SubB2M SPR-based assay to enhance specificity with a non-sialic acid binding version of SubB2M, SubBA12, to control for any non-specific binding to SubB2M, which improved discrimination of cancer-free controls from early-stage ovarian cancer. Using this new assay, sera from breast cancer cases were analysed, revealing significantly elevated levels of Neu5Gc biomarkers at all stages of breast cancer. We show that Neu5Gc serum biomarker levels can discriminate breast cancer patients from cancer-free individuals with high sensitivity and specificity. Analysis of serum collected prospectively, post-diagnosis, from breast cancer patients at high risk for disease recurrence showed a trend for a decrease in Neu5Gc levels immediately following treatment for those in remission. Neu5Gc serum biomarkers are a promising new tool for early detection and disease monitoring for breast cancer that may complement current imaging- and biopsy-based approaches.

scholarly journals Serum biomarker 3144 m/z for prognostic detection in Chinese postmenopausal breast cancer patients

2015 ◽  
Vol 11 (5) ◽  
pp. 68
Author(s):  
Xiaojia Wang ◽  
Dehong Zou ◽  
Yun Gao ◽  
ShenHua Xu ◽  
Wenming Cao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Postmenopausal Breast Cancer ◽  
Serum Biomarker ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document